Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 03, 2024 08:00 ET | Source: VYNE Therapeutics Inc.

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

BRIDGEWATER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative...
November 13, 2023 07:45 ET | Source: VYNE Therapeutics Inc.

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025 Phase 2b preparatory activities progressing for...
November 07, 2023 08:00 ET | Source: VYNE Therapeutics Inc.

VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

Event will highlight VYN201 Phase 1b trial results, VYN202 preclinical data and VYNE’s clinical development plans Program to feature KOL presentation covering unmet need and current treatment...
November 01, 2023 16:15 ET | Source: VYNE Therapeutics Inc.

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

BRIDGEWATER, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative...
October 30, 2023 07:20 ET | Source: VYNE Therapeutics Inc.

VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202

Treatment with VYN202 resulted in significant inhibition of key inflammatory biomarkers and substantial resolution of the signs and symptoms of psoriasis and rheumatoid arthritisFollowing completion...
October 30, 2023 07:05 ET | Source: VYNE Therapeutics Inc.

VYNE Therapeutics Announces Private Placement of $88 Million

BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative...
October 30, 2023 07:00 ET | Source: VYNE Therapeutics Inc.

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

Clinical proof-of-concept achieved with statistically significant dose dependent reduction in F-VASI score from baseline for the VYN201 1.0% and 2.0% cohorts compared to the 0.5% cohort VYN201 was...
September 06, 2023 08:00 ET | Source: VYNE Therapeutics Inc.

VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

BRIDGEWATER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary,...
August 14, 2023 08:00 ET | Source: VYNE Therapeutics Inc.

VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Anticipate announcing preliminary Phase 1b safety and efficacy data for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in Q3 2023 IND-enabling studies for VYN202, a potential...
May 18, 2023 08:00 ET | Source: VYNE Therapeutics Inc.

VYNE Therapeutics to Attend BIO International Convention

BRIDGEWATER, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary,...